THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
99.88%
Total 13F principal
$96,265,501
Principal change
-$20,807,574
Total reported market value
$96,256,968
Number of holders
19
Value change
-$20,425,493
Number of buys
9
Number of sells
7

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q4 2022

As of 31 Dec 2022, THERAVANCE INC - CORPORATE OBLIG was held by 19 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $96,265,501 in principal (par value) of the bond. The largest 10 bondholders included Radcliffe Capital Management, L.P., OAKTREE CAPITAL MANAGEMENT LP, WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., PIPER SANDLER & CO., Russell Investments Group, Ltd., Monashee Investment Management LLC, DEUTSCHE BANK AG\, COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS, and TORONTO DOMINION BANK. This page lists 19 institutional bondholders reporting positions for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.